The chronic inflammatory skin disorder known as prurigo nodularis often presents with intense pruritus and firm nodules that appear across the extremities. Because it can often go unrecognized due to it overlapping with other skin conditions, diagnosis can be delayed and as a result, patients' quality of life can be greatly affected by the physical and social discomfort the disease may cause.

Today, we are taking a look at the latest information regarding prurigo nodularis in relation to clinical guidance, FDA approvals, and clinical trials.

Current Prurigo Nodularis Guidelines

Published in March 2026, the British Association of Dermatologists (BAD) published a guideline for managing patients living with prurigo nodularis. The guideline features 27 recommendations that span general management, topical therapy, phototherapy, antihistamines, neuropathic agents, systemic therapy, cryotherapy, psychological support, and follow-up care.

Managing People with Nodular Prurigo (Prurigo Nodularis)

  • British Association of Dermatologists
  • Published: March 2026
Recent FDA Approvals for Prurigo Nodularis

Below are medications recently approved by the FDA that we anticipate being incorporated into future clinical guidelines: 

Nemluvio (nemolizumab-ilto)

  • Galderma
  • Approved: August 2024
  • Indicated for the treatment of adults with prurigo nodularis.

Dupixent (dupilumab)

  • Sanofi / Regeneron
  • Approved: September 2022
  • Indicated for the treatment of adult patients with prurigo nodularis.
Ongoing Clinical Trials Related to Prurigo Nodularis

The following are ongoing, Phase 3 clinical trials based in the United States that we anticipate may impact future prurigo nodularis clinical guidelines:

Sign up for alerts to keep up with the latest guidelines and insights.